Raymond James analyst Gary Nachman raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $75 from $68 and keeps a Strong Buy rating on the shares after hosting CEO Brett Monia as part of the firm’s BioPharma CEO Strategy Series. Ionis has shown it can execute well commercially with Tryngolza for familial chylomicronemia syndrome, which bodes well for the recent second wholly-owned launch of Dawnzera for hereditary angioedema where early physician/patient sentiment is positive/promising, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals Reports Positive Study Results for Zilganersen
- Ionis Pharmaceuticals reports zilganersen study met primary, secondary endpoints
- Ionis Pharmaceuticals: Strategic Positioning and Growth Potential with Olezarsen’s EU Approval and Promising sHTG Market Prospects
- Ionis Pharmaceuticals announces Tryngolza approval in European Union
- Arrowhead files complaint for declaratory judgment against Ionis